Physician profile
Christopher Donovan
NPI 1770945982
$6,245.27
in general payments reported to CMS, 2019-2025
23 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $128 · 2021: $29.51 · 2022: $467 · 2023: $1,426 · 2024: $1,808 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,241.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $942.10 | 2020-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Photrexa |
| Alcon Vision LLC | $783.27 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Mallinckrodt Hospital Products INC. | $651.87 | 2023-2025 | Acthar |
| Dompe US, INC. | $434.60 | 2023-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $424.73 | 2023-2024 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $401.72 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $324.36 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Amgen INC. | $278.02 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $270.58 | 2022-2025 | |
| Ocular Therapeutix, INC. | $245.89 | 2023-2025 | Dextenza |
| Allergan, INC. | $216.50 | 2019-2020 | |
| Abbvie INC. | $208.26 | 2023-2025 | Durysta |
| Horizon Therapeutics Plc | $177.69 | 2023 | Tepezza |
| Novocure INC. | $162.91 | 2023 | Optune |
| Rxsight INC | $135.08 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $120.48 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $114.82 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $106.70 | 2023-2024 | Cequa |
| Oyster Point Pharma, INC. | $81.06 | 2023-2024 | Tyrvaya |
| Harrow Eye, LLC | $72.74 | 2025 | |
| Rayner Intraocular Lenses Limited | $31.90 | 2025 | Omidria |
| Johnson & Johnson Surgical Vision, INC. | $30.48 | 2024 | Tecnis Iol |
| Ivantis, INC | $29.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.